Cardiovascular Summit 2000: Heart Failure Drugs
	SMi Conferences Ltd. , The Hatton, London 2nd and 3rd October
	SMi’s conference Innovations in Cardiovascular Drugs will tackle issues in this area. For a complete programme please visit our website www.smi-online.co.uk/pharma. As a quick guide, the following topics will be addressed:  Myocardial re-modelling and potential new targets  SERCA2a as a therapeutic target  Endothelin antagonists  Developing diuretics  Gene therapy in heart failure  Membrane transporters as targets
	Organized by:	SMi Conferences
	Invited Speakers:	 Dr Antoine Bril, Director Cardiovascular Research, SmithKline Beecham  Dr Giora Feuerstein, Senior Director, Cardiovascular, DuPont Pharmaceuticals  Dr John Egan, Executive Director, Licensing and Technology Development, Alteon  Dr Arthur Rushton, Development Director, Proteus International  Dr Stephen Mento, President & CEO, Idun Pharmaceuticals  Prof John Cleland, Foundation Chair in Cardiology, University of Hull  Dr Sian Harding, Reader in Cellular Pharmacology, Imperial College School of Medicine
	Deadline for Abstracts:	1st October 2000
	Registration:	Delegate Fee: £999.00 (excluding VAT).
	Email for Requests and Registration:	customer_services@smiconferences.co.uk
	Posted by: Frances Denny   Host: 213.38.112.46 date: August 15, 2000 9:34:51 Generated by meetings and positions 2.0 by Kai Garlipp Logo and Logo Images by Art for BioMed / Syrinx GmbH - Frankfurt / Germany. 4.1 (c) 1995-99 HUM-MOLGEN. All rights reserved. Liability and Copyright.